A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Multiple Dose Escalation Study To Evaluate The Safety, Toleration, Pharmacokinetics Of PF-03049423 In Healthy Young Adult Volunteers And Healthy Elderly Volunteers
Latest Information Update: 05 May 2014
At a glance
- Drugs PF 3049423 (Primary)
- Indications Stroke
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 05 May 2014 New trial record